Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

• Published in: European journal of cancer (1990) Vol. 27; no. 3; p. 248
• Main Authors: van der Burg, M E, Hoff, A M, van Lent, M, Rodenburg, C J, van Putten, W L, Stoter, G
• Format: Journal Article
• Language: English
• Published: England 1991
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - adverse effects; Carboplatin - therapeutic use; Cisplatin - administration & dosage; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms - drug therapy; Prognosis; Thrombocytopenia - chemically induced
• ISSN: 0959-8049
• DOI: 10.1016/0277-5379(91)90507-a

30 ovarian cancer patients with a relapse after prior cisplatin combination chemotherapy were treated in a phase II study with cyclophosphamide 100 mg/m2 orally on days 1-7 and carboplatin 300 mg/m2 intravenously on day 8. Treatment was well tolerated. The major side-effect was thrombocytopenia. 28 patients were evaluable for response. The response was 5 CRs (18%), 4 PRs (14%) 15 SDs (53%) and 4 PDs (14%), for an overall response rate of 32%. The overall progression-free survival lasted from 2 to 23 months, median 8 months. Overall survival ranged from 2 to 35+ months, median 12 months. Patients with a therapy-free interval of more than 1 year showed a higher response rate (46%) than patients with a shorter therapy-free interval (20%). It is concluded that platinum containing second-line chemotherapy, after treatment that already contained cisplatin, is only warranted to palliate symptoms.